Dextenza in the Post-op Management of Vitreoretinal Surgeries
Status:
Enrolling by invitation
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study will assess the control of inflammation at days 1, 7, 14, and 21 days following
the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular
dexamethasone insert group or topical steroid drop group.
Patients must be 18 years of age and older, of any race and either sex, requiring surgery
with the procedure type of pars plana vitrectomy for either the indication of macular hole,
epiretinal membrane removal, or vitreomacular traction.